Mier J W, Atkins M B
Division of Hematology-Oncology, New England Medical Center, Boston, MA 02111.
Curr Opin Oncol. 1993 Nov;5(6):1067-72. doi: 10.1097/00001622-199311000-00020.
More than two dozen cytokines are now available as recombinant proteins suitable for in vivo testing. Several of these novel biologic response modifiers have been evaluated in clinical trials, and a few have been proven to be effective. Interferon-alpha is often used to treat low-grade lympho- and myeloproliferative diseases, and it is undergoing evaluation as treatment of several solid tumors. Interleukin-2 was recently approved by the US Food and Drug Administration for the treatment of patients with metastatic renal cell carcinoma. Other cytokines that are active as antitumor agents in experimental animals have failed to enter the mainstream of oncologic practice because of poor results in preliminary trials and, in some instances, prohibitive toxicity. This review focuses on the cellular mechanisms underlying cytokine-induced tumor regression and toxicity.
现在有二十多种细胞因子作为适合体内测试的重组蛋白可供使用。其中几种新型生物反应调节剂已在临床试验中进行了评估，有几种已被证明是有效的。α干扰素常用于治疗低度淋巴细胞和骨髓增殖性疾病，目前正在评估其对几种实体瘤的治疗效果。白细胞介素-2最近被美国食品药品监督管理局批准用于治疗转移性肾细胞癌患者。其他在实验动物中作为抗肿瘤剂具有活性的细胞因子，由于在初步试验中结果不佳，以及在某些情况下毒性过高，未能进入肿瘤学实践的主流。本综述重点关注细胞因子诱导肿瘤消退和毒性的细胞机制。
